



ARTICLE

Treg expression of CIS suppresses allergic airway inflammation through antagonizing an autonomous TH2 program

Handong Zheng¹, Xiang Wu^{1,2}, Dandan Wu^{1,3,4}, Ruo-Lan Jiang^{1,2}, Eliseo F. Castillo⁵, Cameron J. Chock¹, Qin Zhou^{1,3}, Meilian Liu³, Chen Dong⁶ and Xuexian O. Yang¹

Maintenance of regulatory T (Treg) cells is crucial for the regulatory function of Treg cells in immune homeostasis and self-tolerance; however, the detailed underlying mechanisms remain elusive. In the current study, we found that the cytokine suppressor CIS (cytokine induced SH-2 protein) is required for maintenance of Treg cell identity. Mice with Treg-specific *Cis*-deficiency displayed aggravated experimental allergic asthma, and in adulthood, developed splenomegaly, lymphadenopathy and spontaneous eosinophilic airway inflammation, accompanied by accumulation of effector memory helper T (TH) cells. *Cis*-deficiency led to the loss of *Foxp3* expression and the decrease in suppressive function of Treg cells. *Cis*-deficient Treg cells expressed TH2 cell signature genes, *Gata3*, *Irf4* and *Ila*, and excessive interleukin-4–signal transducer and activator of transcription 6 (IL-4–STAT6) signals resulted in repressive chromatin modification in the *Foxp3* locus and permissive modification in the *Ila* loci. In vitro, blockade of IL-4 restored the expression of *Foxp3* and the suppressive function of inducible Treg (iTreg) cells. Thus, we identified a novel feedback loop in stabilization of Treg cells and suppression of TH2-type inflammation in a Treg-intrinsic manner.

Mucosal Immunology (2020) 13:293–302; <https://doi.org/10.1038/s41385-019-0236-3>

INTRODUCTION

CD4⁺CD25⁺Foxp3⁺ regulatory T (Treg) cells play a crucial role in the maintenance of self-tolerance and immune homeostasis.^{1,2} Treg cells are classified into two major subsets, thymus-derived Treg [tTreg, or natural Treg (nTreg)] cells and peripherally developed Treg (pTreg) cells. In vitro-generated inducible Treg (iTreg) cells also possess suppressive function, but rapidly lose *Foxp3* expression in vivo.³ *Foxp3*, the master and signature transcription factor of Treg cells, governs the development, self-maintenance, and function of both tTreg and iTreg cells.^{4,5} In humans, mutation or deletion of gene encoding *Foxp3* leads to Treg cell dysfunction or deficiency, resulting in severe autoimmune diseases.⁶ In contrast, forced overexpression of *Foxp3* in conventional T cells confers suppressive activity,^{7,8} suggesting a pivotal role of *Foxp3* in mediating Treg cell function. Manipulation of Treg cells is a promising immune therapy for autoimmune and inflammatory diseases, such as type 1 diabetes, graft-versus-host disease and inflammatory bowel disease.^{9–12} However, destabilization of Treg cells is associated with a variety of inflammatory diseases, including allergic disorders and presents a huge hurdle for their therapeutic potentials.^{13–17}

Signal transducer and activator of transcription (STAT) proteins are one of the most common cytokine signaling mediators, and cytokine-induced STAT signaling presents as a major factor

affecting Treg cell stability. It has been shown that interleukin-6 (IL-6) activates STAT3 to drive the loss of *Foxp3* expression in Treg cells, followed by the reprogramming of Treg towards helper T type 17 (TH17) cells.^{13,16,18} Additionally, IL-4-induced STAT6 signaling also destabilizes Treg cells.^{14,15,19,20} Activated STAT3 and STAT6 undergo nuclear translocation, bind to the *Foxp3* locus, and diminish *Foxp3* expression.^{19,21} Thus, the activation of STATs by inflammatory cytokines in milieu is one of the most important factors affecting Treg cell stability.

STAT signals are controlled by several negative regulatory strategies.^{22–24} The suppressor of cytokine signaling (SOCS) family proteins are broadly involved in negative regulation of STAT signaling. In this study, we found that CIS (cytokine-induced SH-2 protein, also termed CIS1, SOCS, and CISH),²⁵ a SOCS family member, plays an essential role in the maintenance of Treg cell identity. CIS has been shown to disrupt STAT5 signaling induced by cytokines and hormones.^{22–24,26,27} In addition, our previous study has showed that CIS also inhibits STAT3 and STAT6 signaling in CD4⁺ T cells.²⁸ Both tTreg and iTreg cells express CIS.²⁸ In the current study, we utilized Treg-specific *Cis*-deficiency mouse model to investigate the role of CIS in Treg cell stability and function. We found that Treg-specific *Cis*-deficiency exacerbated experimental asthma, and in adult mice, resulted in spontaneous eosinophilic airway inflammation. The exacerbated inflammatory

¹Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA; ²Department of Parasitology, School of Basic Medical Sciences, Xiangya School of Medicine, Central South University, Changsha, China; ³Department of Biochemistry and Molecular Biology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA; ⁴College of Agronomy, Hunan Agricultural University, Changsha, Hunan 410128, China; ⁵Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA and ⁶Institute of Immunology and School of Medicine, Tsinghua University, Beijing 100084, China
Correspondence: Xuexian O. Yang (xyang@salud.unm.edu)

These authors contributed equally: Handong Zheng, Xiang Wu, Dandan Wu

Received: 7 February 2019 Revised: 17 October 2019 Accepted: 12 November 2019

Published online: 28 November 2019






Fig. 1 Treg-specific *Cis*-deficient mice spontaneously develop splenomegaly, lymphadenopathy, and chronic lung inflammation. **a** Spleen- and lung-associated mediastinal LNs (LLNs) of 6-month-old *Cis*^{fl/+},Cre and *Cis*^{fl/fl},Cre mice. **b** H&E stain of left lung lobes from mice in **a**. Scale bar, 100 μm. **c** Cellular profiles of lung infiltrates. **d** Cellular profiles of CD4⁺CD25⁻ T cells in LLNs, spleens, inguinal lymph nodes (InLNs), and mesenteric lymph nodes (MLNs). **e** Statistical analysis of effector memory TH cells (Tem) in **d**. **c**, **e** Data are a representative of two experiments (4–5 mice per group). Values are means and SD. Student's *t* test, **p* < 0.05, ***p* < 0.005, and ****p* < 0.0005.

responses were due to impaired suppressive function of *Cis*-deficient Treg cells, which was associated with activation of an endogenous TH2 cell programs. Excessive IL-4-STAT6 signals drove the loss of Foxp3 expression in Treg cells. Concluding, CIS stabilizes Treg cells through inhibition of a Treg-intrinsic TH2 program and negatively control allergic airway inflammation.

RESULTS

Treg-specific *Cis*-deficiency leads to spontaneous chronic inflammation with enhanced T effector programs
We have previously shown that *Cis*-deficiency on the B6 background leads to spontaneous airway disease with aging, associated with increased TH2 and TH9 cell responses.²⁸ Genetic background is known to shape gene function. On a 129;B6 mixed background, *Cis*-deficiency caused severe splenomegaly and lymphadenopathy (Supplementary Fig. 1), resembling Treg-deficiency-induced autoimmune diseases. Thus, we conceived that CIS may be required for the function of Treg cells. To validate this, we generated Treg-specific *Cis*-deficient mice, *Cis*^{fl/fl};Foxp3-YfpCre (*Cis*^{fl/fl},Cre) mice on the 129;B6 F1 background (hereafter, the mice will be all on the 129;B6 F1 background) by breeding B6.*Cis*^{fl/fl},Cre with 129.*Cis*^{fl/+} (the latter was generated by crossing B6.*Cis*^{fl/fl} with 129 mice for 7–8 generations). The deletion of *Cis* in Treg cells was confirmed by real-time quantitative (RT-qPCR) (Supplementary Fig. 2). We first examined the inflammatory phenotypes and TH cell profiles in *Cis*^{fl/fl},Cre mice compared with their *Cis*^{fl/+},Cre littermates (*Cis*^{fl/+},Cre mice had a similar phenotype as *Cis*^{fl/fl} and *Cis*^{+/+},Cre mice; data not shown). At the age of 6 months, *Cis*^{fl/fl},Cre mice exhibited apparent splenomegaly and lymphadenopathy (Fig. 1a), coupled with aggravated lung inflammation relative to the control mice (Fig. 1b). The lungs of *Cis*^{fl/fl},Cre mice displayed significantly more immune infiltrates, including lymphocytes, eosinophils and macrophages

(Fig. 1c). We also assessed the kidney and pancreas, but did not observe appreciable immune infiltrates (data not shown). Since Treg cells are essential in the maintenance of immune homeostasis, we asked whether *Cis*-deficiency in Treg cells affects T effector cell programs. We measured the frequencies of effector memory CD4⁺ T cells in 6-month-old animals and found that *Cis*^{fl/fl},Cre mice displayed significantly increased CD4⁺CD25⁻CD44^{hi}C62L⁻ effector memory T cells in lung-draining mediastinal lymph nodes (LLNs), inguinal and mesenteric lymph nodes, and spleen compared with *Cis*^{fl/+},Cre mice (Fig. 1d, e). Furthermore, we analyzed the CD4⁺ T compartment by intracellular stain of respective signature cytokines, and found that *Cis*^{fl/fl},Cre mice had significantly higher frequencies and numbers of TH1, TH2, and TH17 cells in the lungs, LLNs, and spleens than *Cis*^{fl/+},Cre mice (Fig. 2a, b). In Peyer's patches, Treg-specific *Cis*-deficiency led to increased frequencies of TH2 cells, but not TH1 and TH17 cells (Supplementary Fig. 3). Interestingly, the elevated inflammatory response in *Cis*^{fl/fl},Cre mice was associated with aging. Young (6–8 weeks old) *Cis*^{fl/fl},Cre and *Cis*^{fl/+},Cre mice both had very few TH1, TH2, and TH17 cells in the lung, and the number of these cells in the lung, LLN, and spleen was comparable between the two groups of mice (Supplementary Figs. 4 and 5). At the age of 6–7 months, *Cis*^{fl/fl},Cre mice had increased serum levels of IL-5 and IL-13, but not IL-17 and interferon-γ (IFNγ) relative to *Cis*^{fl/+},Cre mice, whereas there were no significant differences in the serum cytokines of 6–8-week-old *Cis*^{fl/fl},Cre and *Cis*^{fl/+},Cre mice (Supplementary Fig. 6). Collectively, these data indicate a pivotal role of CIS in maintaining the regulatory function of Treg cells during aging.

Treg-specific *Cis*-deficiency enhances experimental asthma
Germline *Cis*-deficiency on the B6 background causes spontaneous airway disease associated with elevated TH2 and TH9 responses.²⁸ Our results above also demonstrate a critical role of




Fig. 2 Treg-specific *Cis*-deficiency enhances T effector programs in secondary lymphoid tissues and lungs. **a** Cytokine expression by CD4⁺ cells in the lung, LLN, and spleen of 6-month-old *Cis*^{fl/+},Cre and *Cis*^{fl/fl},Cre mice. **b**, **c** Statistical analysis of **a**. Data are a representative of two experiments (4–5 mice per group). Values are means and SD. Student's *t* test, **p* < 0.05, ***p* < 0.005, and ****p* < 0.0005.

Treg-specific *Cis*-deficiency in lung inflammation and immune homeostasis. We asked whether Treg-specific *Cis*-deficiency also plays a role in allergic airway inflammation. To answer this question, we employed an experimental allergic asthma model using a standard protocol as described before.^{29,30} Young *Cis*^{fl/fl},Cre mice (6–8 weeks old) had only a few lung infiltrates, but were otherwise healthy (Supplementary Fig. 4). After induction of allergic asthma, we assessed the cellular profiles of bronchoalveolar lavage fluids (BALFs) and found that *Cis*^{fl/fl},Cre BALFs contained more CD4⁺ T lymphocytes and eosinophils than *Cis*^{fl/+},Cre BALFs (Fig. 3a). Histological analyses further confirmed that *Cis*^{fl/fl},Cre lungs had more immune infiltrates than the *Cis*^{fl/+},Cre counterparts (Fig. 3b). The asthmatic *Cis*^{fl/fl},Cre mice had increased frequencies of TH2 cells in the BALF, LLN, and spleen (Fig. 3c, d) relative to *Cis*^{fl/+},Cre mice. Moreover, upon ex vivo recall with chicken ovalbumin (OVA), a model antigen used to elicit asthma, *Cis*^{fl/+},Cre LLN cells and splenocytes secreted significantly higher amounts of TH2 cytokines, IL-4, IL-5, and IL-13, but not TH1 cytokine IFN γ , than *Cis*^{fl/+},Cre cells (Fig. 3e). In the *Cis*^{fl/fl},Cre lung, we also observed increased frequencies of TH2 cells with no change in TH1 cells (Supplementary Fig. 7).

Next, we assessed whether *Cis*-deficiency in Treg cells affects asthmatic responses by using an adoptive transfer system. This was achieved by transfer of *Cis*-deficient (or -sufficient) Treg cells with Treg-depleted *Cis*-sufficient CD4⁺ T cells to prevent egress of tTreg cells into the environment as well as de novo generation of *Cis*-deficient iTreg cells. In agreement with our

above observation, we found that mice receiving *Cis*^{fl/fl},Cre Treg cells had increased TH2 responses and eosinophilia relative to those receiving *Cis*^{fl/+},Cre Treg cells (Supplementary Fig. 8). Together, these data suggest that CIS plays a crucial role in maintaining Treg-suppressive function during allergic inflammation, and the loss of CIS in Treg cells results in exacerbate allergic responses.

Cis-deficiency leads to decreased Foxp3 expression and suppressive function of Treg

Since our above results demonstrate a crucial role of CIS in Treg cells in maintaining immune homeostasis in vivo, we asked whether CIS directly affects Treg-suppressive function. To explore this, we isolated CD4⁺Foxp3-GFP⁺NRP1^{hi} tTreg cells by fluorescence-activated cell sorting (FACS) sorting from *Cis*^{-/-}; *Foxp3-Gfp* (*Cis*^{-/-},GFP) and *Cis*^{+/+},GFP mice to assess their suppressive function. Additionally, we polarized naive CD4⁺ T cells from the above mice towards iTreg cells and purified Foxp3-expressing cells using a CD4⁺Foxp3-GFP⁺ gate. The suppressive function of tTreg and iTreg cells (both purity >99%) were assessed by measuring ³H-thymidine incorporation of effector CD4⁺ T cells during proliferation. We found that *Cis*-deficiency resulted in impaired suppressive function of tTreg cells as well as iTreg cells, whereas the impairments were more pronounced in iTreg cells (Fig. 4a, b). Together, these data demonstrate that CIS is required for the maintenance of both iTreg and tTreg cell-suppressive function.




Fig. 3 Treg-specific *Cis*-deficiency enhances allergic asthma. **a** Cellular profile of bronchoalveolar lavage fluids (BALFs) of *Cis*^{fl/+},Cre and *Cis*^{fl/fl},Cre mice after induction of asthma. **b** H&E stain of left lung lobes from mice in **a**. Scale bar, 100 μ m. **c** Intracellular stain of TH2 cytokines in the BALF, LLN, and spleen. **d** Statistical analysis of **c**. **e** ELISA of cytokine expression by LLN cells and splenocytes following recall with ovalbumin (OVA) at indicated concentrations for 3 days. Data are a representative of three (**a–d**) and two (**e**) independent experiments (4–5 mice per group). Values are means and SD. Student’s *t* test, **p* < 0.05 and ***p* < 0.005.

As we know, Foxp3, the master transcription factor, governs the development, maintenance, and function of Treg cells.^{4,5} Thus, we assessed Foxp3-expressing Treg cells in LLNs from 6-month-old *Cis*^{fl/+},Cre and *Cis*^{fl/fl},Cre mice by flow cytometry following intracellular stain and found comparable percentages and numbers of Foxp3⁺ cells in CD4⁺ T populations (Supplementary Fig. 9A). Although *Cis*-deficiency in Treg cells did not affect the frequencies and numbers of the Treg cells population, it led to lower expression of Foxp3 in both tTreg and iTreg cells (Fig. 4C, Supplementary Fig. 10), indicating a pivotal role of CIS in sustaining Foxp3 expression in Treg cells in vivo and in vitro. Together, these data suggest that CIS is required for maintaining Foxp3 expression in Treg cells.

***Cis*-deficiency drives loss of Treg cell identity and activates effector programs**

Our above findings suggest that *Cis*-deficiency results in decreased expression of Foxp3 and impaired function of Treg cells. We then asked whether CIS is required for maintenance of Treg cell identity. To address this, we employed a Treg cell fate-mapping mice model,

in which Foxp3-YFPCre excised a floxed stop code sequence and led to constitutive expression of enhanced YFP from the *Rosa26*^{stop}-*eYfp* (R26Y) locus that marked Foxp3^{lo} (that partially lost Foxp3 expression) and Foxp3^{hi} Treg cells. We analyzed the Treg cell fate in splenocytes from 6-month-old *Cis*^{fl/+},Cre R26Y and *Cis*^{fl/fl},Cre R26Y mice with a CD4⁺YFP⁺ gate. As expected, *Cis*^{fl/fl},Cre R26Y cells displayed a higher frequency of Foxp3^{lo} Treg cells compared with control cells (Fig. 5a), suggesting a critical role of CIS in Treg cell stability. Interestingly, albeit *Cis*-deficiency led to decreased Foxp3 expression in Treg cells, we observed similar frequencies and numbers of Treg cells in LLNs of *Cis*^{fl/fl},Cre mice compared with *Cis*^{fl/+},Cre controls (Supplementary Fig. 9A and data not shown). This may be explained by higher proliferation rates of *Cis*^{fl/fl},Cre over *Cis*^{fl/+},Cre Treg cells as measured by the proliferation status marker Ki67 (Supplementary Fig. 9B). We next asked whether Foxp3^{lo} Treg cells could maintain the expression of Treg-associated functional molecules. We found that *Cis*-deficient (and -sufficient) Foxp3^{lo} Treg cells lost the expression of CD25, but largely remained the expression of NRP1 and had comparable levels of PD1 (Supplementary Fig. 11A). Interestingly, *Cis*^{fl/fl},Cre mice had more




Fig. 4 *Cis*-deficiency leads to decreased Foxp3 expression in Treg cells and impaired their suppressive activity. **a**, **b** ³H-thymidine incorporation of effector CD4⁺ T cells in the presence or absence of **a** tTreg (CD4⁺Foxp3-GFP⁺Nrp-1^{hi}) cells isolated from *Cis*^{fl/+},GFP⁺ and *Cis*^{-/-},GFP⁺ mice or **b** purified Foxp3-GFP⁺ WT and *Cis*^{-/-} iTreg cells differentiated from naive cells of above mice. Teff, effector T cells. **c** Immunoblot of Foxp3 expression in purified *Cis*^{fl/fl},Cre and *Cis*^{fl/+},Cre tTreg cells and iTreg cells. β -Actin was used as a loading control. Right, statistical analysis of Foxp3 abundances relative to β -actin. Data are a combination of two (**a**, **b**, $n = 4-6$ biological replicates per group) or four (**c**) experiments. Values are means and SD. Student's *t* test, * $p < 0.05$ and ** $p < 0.005$.

CD25^{lo}Foxp3^{lo}, Nrp1^{lo}Foxp3^{lo}, and PD1^{lo}Foxp3^{lo} cells in the CD4⁺YFP⁺ compartment than *Cis*^{fl/+},Cre mice. Furthermore, CIS did not affect the expression of CD39, CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and ICOS (inducible co-stimulator) in either Foxp3^{hi} or Foxp3^{lo} Treg cells (Supplementary Fig. 11B). Together, our data suggest that *Cis*-deficiency diminishes the expression of Foxp3 and CD25, which, at least in part, accounts for the impaired suppressive function of *Cis*-deficient Treg cells.

Our above results indicate that *Cis*-deficiency impaired Treg cell program. Nevertheless, it remains unclear whether *Cis*-deficiency leads to adoption of effector programs in Treg cells. To test this, we assessed the expression of effector cytokines in Treg-originated cells from the fate-mapping mice, and found that, indeed, CD4⁺YFP⁺ LLN cells from 6-month-old *Cis*^{fl/fl},Cre R26Y mice contained more IL-4/IL-5⁺ TH2 and IL-17⁺ TH17 cells, but not IFN γ ⁺ TH1 cells compared with those from *Cis*^{fl/+},Cre R26Y mice (Fig. 5b). Interestingly, conventional CD4⁺YFP⁻ LLN cells from *Cis*^{fl/fl},Cre R26Y mice also contained more TH2 cells than the *Cis*^{fl/+},Cre R26Y counterparts (Fig. 5b), in agreement with the impaired Treg cell function. To further understand whether Foxp3^{lo} or Foxp3^{hi} Treg cells express effector cytokines, we co-stained Foxp3 with the effector cytokines and found that both Foxp3^{lo} and Foxp3^{hi} Treg cells from *Cis*^{fl/fl},Cre R26Y and *Cis*^{fl/+},Cre R26Y mice contained a small portion of cytokine-expressing cells, but there were no differences between the two groups (Supplementary Fig. 12). Our data suggest that CIS expression in Treg cells silences TH effector programs regardless of Foxp3 expression status.

CIS antagonizes IL-4 signals to maintain Treg cell function

To gain further insights into how CIS regulates the stability and function of Treg cells, we profiled the gene expression patterns in the presence or absence of CIS. CD4⁺YFP⁺ (Foxp3⁺) CD25⁺ Treg cells were FACS sorted from *Cis*^{fl/fl},Cre and *Cis*^{fl/+},Cre mice and messenger RNA (mRNA) expressions of genes associated with various TH cell programs were assessed by RT-qPCR. In alignment with our above results, mRNA expression of transcription factor Foxp3 and IL-2 receptor CD25 (but not the common γ -chain) was downregulated in *Cis*-deficient Treg cells relative to *Cis*-sufficient counterparts (Fig. 6a, Supplementary Fig. 13). Surprisingly, mRNA expression of anti-inflammatory cytokine IL-10 was increased in

Cis-deficient Treg cells compared with *Cis*-sufficient Treg cells, which might reflect an effector but not regulatory T cell program since effector T cells express various amounts of IL-10. *Cis*-deficiency did not alter the expression of CTLA-4, transforming growth factor- β (TGF β), and IL-35 (encoded by *p35* and *Ebi3*, although *Cis*-deficiency increased the expression of *Ebi3*). Noteworthy, *Cis*-deficiency resulted in increased expression of TH2 signature genes, including those encoding cytokine IL-4, and transcription factors, GATA3 and IRF4 (and a trend of increase in IL-4Ra) (Fig. 6a). In line with this, *Cis*-deficiency promoted the expression of TH2 genes in either CD4⁺CD25^{lo}YFP⁺ (containing Foxp3^{lo} cells) or CD4⁺CD25^{hi}YFP⁺ (Foxp3^{hi}) Treg cells sorted from the fate-mapping mice, but only downregulated Foxp3 expression in CD4⁺CD25^{lo}YFP⁺, but not CD4⁺CD25^{hi}YFP⁺ population, suggesting that the upregulation of the TH2 program might be an earlier event than the loss of Foxp3 in *Cis*-deficient Treg cells (Supplementary Fig. 14). In addition, *Cis*-deficiency also led to a trend of increases in the expression of other TH program genes, such as *Tbx21* (encoding TH1 transcription factor T-bet), *Rorgt* (encoding TH17 transcription factor ROR γ t), and *Il17* (Fig. 6a). By using enzyme-linked immunosorbent assay (ELISA), we found that *Cis*-deficient Treg cells expressed heightened amounts of TH2 cytokines, IL-4 and IL-5, but not TH17 cytokine IL-17 and TH1 cytokine IFN γ compared with *Cis*-sufficient counterparts (Fig. 6b). Similarly, we observed an increase in mRNA expression of *Irf4* and *Il4*, and a decrease in the expression of *Foxp3* in purified *Cis*^{-/-} relative to *Cis*^{fl/+} iTreg cells (Supplementary Fig. 15). In summary, these findings confirmed that *Cis*-deficient Treg cells generated both in vivo and in vitro possess the propensity to lose Treg tolerance program and to gain T effector programs, especially the TH2 program that may serve as an early source of IL-4, promoting conventional TH2 cell differentiation and accumulation.

We next examined whether Treg cell-specific *Cis*-deficiency inhibits iTreg cell polarization through the induction of a Treg-intrinsic TH2 cell program. *Cis*-deficient T cells displayed increased TH2 cell responses as well as decreased differentiation of iTreg cells, which could be neutralized by blocking IL-4 in vitro.²⁸ We further showed Treg cell-specific *Cis*-deficiency also resulted in a decrease in polarization of Foxp3⁺ cells and treatment with anti-IL-4 rescued Foxp3⁺ iTreg cell induction (Supplementary Fig. 16).




Fig. 5 *Cis*-deficiency results in loss of Treg cell identity and activation of effector programs. **a** Intracellular stain of Fcγ3 in LLN CD4⁺YFP⁺ Treg cells from 6-month old *Cis*^{fl/fl,Cre} R26Y and *Cis*^{fl/fl,Cre} R26Y mice. Right, statistical analysis of Fcγ3^{lo} Treg (CD4⁺YFP⁺Fcγ3^{lo}) cells. Box indicates the 1st and 3rd quartiles and whiskers indicate the maximum and minimum. "X" indicates mean point. *n* = 8 mice per group. **b** Intracellular stain of cytokine-expressing cells in LLNs from 6-month-old *Cis*^{fl/fl,Cre} R26Y and *Cis*^{fl/fl,Cre} R26Y mice on a CD4⁺ gate. Data represent two experiments (*n* = 4 mice per group). Values are means and SD. Student's *t* test, **p* < 0.05.

This indicates a pivotal role of Treg expression of CIS in inhibition of IL-4 signals during iTreg cell polarization. To understand how CIS antagonizes pro-inflammatory cytokine signals and stabilizes Treg cells, we cultured purified *Cis*-deficient and -sufficient iTreg cells on a plate coated with anti-CD3 and anti-CD28 in the presence of IL-2 with or without blockade of cytokine signals. We found that after treatment with a control antibody, *Cis*-deficiency resulted in dramatic loss of Fcγ3, whereas anti-IL-4 treatment largely restored Fcγ3 expression in *Cis*-deficient iTreg cells (Fig. 6c). Interestingly, treatment with anti-IL-6 plus IL-21R (blocking the TH17 pathway) or anti-IFNγ (blocking the TH1 pathway) only slightly prevents the loss of Fcγ3 expression in *Cis*-deficient iTreg cells. Therefore, CIS plays a critical role in guarding Treg cell stability by inhibiting a TH2-dominant effector program. We then asked whether *Cis*-deficiency impairs Treg cell function through IL-4 signals. To answer this, we examined the regulatory function of purified *Cis*-deficient and -sufficient iTreg cells in the presence or absence of IL-4-neutralizing antibody. As expected, *Cis*^{-/-} iTreg cells had impaired suppressive function compared with *Cis*^{+/+} iTreg, whereas the attenuated function of *Cis*^{-/-} iTreg cells was restored by the addition of anti-IL-4, but not a control antibody into the culture (Fig. 6d), suggesting a central role of CIS in governing IL-4 signals in regulating Treg-suppressive function.

CIS inhibits STAT6 binding to and silencing the *Foxp3* locus
As mentioned above, STAT6 phosphorylation is the major downstream signal event in response to IL-4 in CD4⁺ T helper

cells. Thus, we examined the effects of CIS on STAT6 activation in Treg cells by intracellular stain. First, we measured in vivo expression of phosphor- (p) STAT6 in Treg cells and observed a slight increase in the levels of pSTAT6 in *Cis*^{fl/fl,Cre} Treg cells compared with *Cis*^{fl/fl,Cre} Treg cells (Fig. 7a). Second, we assessed pSTAT6 expression in iTreg cells polarized from *Cis*^{fl/fl,Cre}- and *Cis*^{fl/fl,Cre}-naive T cells and found that *Cis*^{fl/fl,Cre} iTreg cells expressed higher amounts of pSTAT6 than the control cells (Fig. 7a). The absence of STAT6 abolished IL-4 expression in *Cis*-deficient Treg cells (Supplementary Fig. 17). Concluding, *Cis*-deficiency led to elevated STAT6 activation in Treg cells, which was likely triggered by autocrine IL-4 induced by activated STAT6.

To understand how *Cis*-deficiency induced IL-4 signaling destabilizes iTreg cells, we performed chromatin immunoprecipitation (ChIP) assays to uncover the transcriptional accessibility of Treg and effector T cell signature gene loci. At the conserved non-coding sequence 2 (CNS2) and the promoter of *Foxp3* gene, pSTAT5 binding is required for the maintenance of Treg cell identity, whereas pSTAT6 was thought to compete with pSTAT5 binding at this locus and may lead to a decrease in expression or even silencing of *Foxp3* gene.^{31–33} We measured the binding levels of pSTAT6 and pSTAT5 at the *Foxp3* locus in iTreg cells in the absence of exogenous IL-4, and found higher pSTAT6 binding to both *Foxp3* promoter and CNS2 regions in *Cis*^{fl/fl,Cre} relative to *Cis*^{fl/fl,Cre} iTreg cells (Fig. 7b, left). There was a trend showing a decrease in pSTAT5 bindings to these two sites in *Cis*^{fl/fl,Cre} iTreg cells compared with that in *Cis*^{fl/fl,Cre} iTreg cells; however, it did




Fig. 6 *Cis*-deficiency impairs Treg cell function in an IL-4 signaling-dependent manner. **a** RT-qPCR of gene expression in CD4⁺Foxp3-YFP⁺CD25⁺ Treg cells sorted from *Cis*^{fl/fl,Cre} and *Cis*^{fl/+Cre} mice. *Ebi3* and *p35* encode IL-35. *Tbx21* encodes T-bet. *Actb* was used as a loading control. **b** ELISA of effector cytokine expression in purified Treg cells from above mice following stimulation with plate-bound α -CD3 and α -CD28. **c** Intracellular stain of Foxp3 in *Cis*^{fl/fl,Cre} and *Cis*^{fl/+Cre} iTreg cells cultured on α -CD3 and α -CD28 coated plate for 8 h in the presence of α -IL-4, α -IL-6 + IL-21R, α -IFN γ , or a control antibody (Ctr). The numbers are the percentages of Foxp3^{lo} cells (*Cis*^{fl/+Cre}/*Cis*^{fl/fl,Cre}). **d** ³H-thymidine incorporation of effector CD4⁺ T cells with α -IL-4 or a control antibody in the presence or absence of purified Foxp3-GFP⁺ WT and *Cis*^{-/-} iTreg cells. Data shown are a representative of two experiments (three biological replicates per group) (**a**, **b**), two (**c**) independent experiments, or a combination of two experiments (4–6 biological replicates per group) (**d**). Values (**a**, **b**, **d**) are means and SD (**b**, **d**). Student's *t* test, **p* < 0.05, ***p* < 0.005.

not reach significance (Fig. 7b, right). These data suggest CIS blocks IL-4-induced activation of STAT6 in iTreg cells and prevents pSTAT6-mediated silence of *Foxp3* expression.

To gain further insight into the role of CIS in stabilization of Treg cells, we assessed epigenetic modifications of histone h3 lysine 4 trimethylation (H3K4m3), indicating permissive epigenetic modification, and H3K27m3, associated with gene inactivation, at the *Foxp3*, *Il4*, and *Il17* loci (Fig. 6a). We observed a dramatic decrease in H3K4m3 modifications on both *Foxp3* promoter and CNS2 regions in *Cis*-deficient relative to *Cis*-sufficient iTreg cells (Fig. 7c, left), although no distinction has been found on H3K27m3 modifications on these sites (Fig. 7d, left). In addition, the H3K4m3 modification at the *Il4* HS2 region, but not the *Il17* promoter was significantly enhanced (Fig. 7c, right), and meanwhile, the H3K27m3 modifications were consistently decreased at the *Il4* HS2 and HS3 regions, as well as the *Il17* promoter in *Cis*^{fl/fl,Cre} compared with that in *Cis*^{fl/+Cre} iTreg cells (Fig. 7d, right). Together, these results unravel that CIS stabilizes Treg cells via

antagonizing IL-4–STAT6 signals that represses the *Foxp3* locus and activates the *Il4* gene.

Taken together, we have uncovered an unappreciated and pivotal role of CIS in maintaining Treg cell identity and function via antagonizing IL-4–STAT6 signaling and stabilizing *Foxp3* expression (summarized in Supplementary Fig. 18).

DISCUSSION

Treg cells are crucial for maintaining immune tolerance and homeostasis in mice and humans. The stability of *Foxp3* expression in Treg cells is considered as a determinant factor of immune homeostasis.^{4,5} Many transcription factors, including STAT5 (activated through IL-2), SMADs (activated through TGF β), NFAT (nuclear factor of activated T cells) and CREB, have been shown to stabilize *Foxp3* expression in Treg cells through targeting CNS2 or other regulatory elements at the *Foxp3* locus.^{3,34} However, under certain pro-inflammatory circumstances,




Fig. 7 *Cis*-deficiency silences the Treg program and promotes a TH2 phenotype through the IL-4-STAT6 axis. **a** Intracellular phosphor-stain of pSTAT6 in tTreg or iTreg cells. **b** ChIP assays of pSTAT6 and pSTAT5 binding onto the *Foxp3* locus in *Cis*^{fl/fl},Cre and *Cis*^{fl/+},Cre iTreg cells. **c, d** ChIP assays of H3K4m3 (**c**) and H3K27m3 (**d**) modifications on the *Foxp3*, *IL-4*, and *IL-17* loci in indicated iTreg cells. Data are a representative of two to three independent experiments (three biological replicates per group). **a** (right), **b–d** Values are means and SD. Student's *t* test, **p* < 0.05, ***p* < 0.005, and ****p* < 0.0005.

Foxp3⁺ Treg cells become unstable and lose *Foxp3* expression and might further adopt a CD4⁺ T effector phenotype. Several studies concerning STATs regulation of *Foxp3* locus showed that IL-4-induced pSTAT6 and IL-6-induced pSTAT3 are enabled to compete for the pSTAT5-binding sites at the *Foxp3* locus and interact with DNA methyltransferases Dnmt1, which is believed to be responsible for de novo DNA methylation,³² leading to diminished *Foxp3* expression.^{19,21} In concert with aforementioned studies, our study provides evidence that dysregulation of pro-inflammatory cytokine signals in *Cis*-deficient Treg cells led to the loss of *Foxp3* expression and impairment of suppressive function of Treg cells. Mice carrying *Cis*-deficient Treg cells manifested a spontaneous phenotype of eosinophilic airway inflammation.

Consistently, Treg cell-specific deletion of *Cis* led to exacerbated type 2 immune responses in an asthma model.

Pro-inflammatory cytokine signaling is largely dependent on STAT protein activation. As one of the classical negative regulatory strategies on STATs signaling, SOCS family proteins are broadly involved in the restriction of STAT activation and stabilization of Treg cells in pro-inflammatory conditions. As shown in previous studies, SOCS1 and SOCS2 are both essential for Treg cell stability. SOCS1 stabilizes Treg cells through inhibiting STAT1 and STAT3 activation,³⁵ whereas SOCS2 maintains pTreg cells likely through inhibition of IL-4-STAT6 signal.³⁶ CIS, another member of the SOCS protein family, has been shown to disrupt STAT5 signaling induced by cytokines and hormones.^{22–24,26,27} In addition, our

previous studies showed that CIS also inhibits STAT3 and STAT6 signaling in CD4⁺ T cells.²⁸ In this study, we found that in the absence of CIS, Treg cells, generated either *in vivo* or *in vitro*, had impaired suppressive function, and diminished Foxp3 expression, which was largely mediated by TH2-type cytokine IL-4, but not TH1 type cytokine IFN γ and TH17-type cytokines IL-21 and IL-6. Consistent with this, we detected increased STAT6 binding to the *Foxp3* locus, accompanied with decreased epigenetic permissive marker H3K4me3 levels on the *Foxp3* CNS and promoter in *Cis*-deficient relative to *Cis*-sufficient Treg cells. Together, these data indicate a critical role of CIS in antagonizing IL-4-mediated STAT6 activation and in the maintenance of chromatin accessibility of the *Foxp3* locus.

GATA3 is the major transcription factor of TH2 cells.³⁷ Treg cells residing in barrier sites also express GATA3 that is required for Treg cell maintenance under inflammatory conditions, but not the steady state,^{38,39} predisposing a risk of instability in Treg cells. In our study, we found that *Cis*-deficiency not only caused loss of Foxp3 expression but also rendered an endogenous TH2 cell program in Treg cells generated *in vivo* with elevation of mRNAs encoding TH2 cell signature transcription factors, GATA3 and IRF4, and cytokine, IL-4. In iTreg cells, *Cis*-deficiency also resulted in increased mRNA expression of *Irf4* and *Ii4*, but did not alter *Gata3* mRNA expression, indicating that increased expression of IL-4 by *Cis*-deficient iTreg cells did not require further upregulation of GATA3. The autocrine IL-4 triggered activation of STAT6 that bound to and occupied the Foxp3 promoter and CNS2. This overloaded IL-4–STAT6 signaling circuit drove the loss of Foxp3 expression in Treg cells, and meanwhile promoted TH2 cell effector cytokine expression, therefore enforcing a feedforward loop that impaired Treg function and led to spontaneous inflammation. Taken together, CIS plays a crucial role in stabilizing Treg cells through antagonizing an autocrine (and maybe also other sourced) IL-4-mediated STAT6 signaling, highlighting a cell-intrinsic circuit important for Treg cell self-maintenance.

As we observed that CIS was required to maintain Treg cell suppressive function via stabilizing the expression of Foxp3, we examined the relationship between CIS and Treg-associated functional molecules. By leverage a Treg-specific reporter system, we observed Foxp3^{lo} Treg cells that were highly present in *Cis*-deficient animals lost expression of CD25, but remained other Treg-associated surface markers, such as CTLA-4, CD39, PD1 and ICOS, suggesting that the Foxp3^{lo} Treg cells may partially remain in their suppressive function. As revealed by intracellular stain, Treg expression of CIS suppressed the expression of effector cytokines, IL-4/IL-5, IL-17, or IFN γ by Treg cells. Interestingly, both Foxp3^{lo} and Foxp3^{hi} Treg cells expressed these effector cytokines even in *Cis*-deficient animals; however, only a few Foxp3^{lo} Treg cells expressed effector cytokines. Therefore, *Cis*-deficiency destabilizes Treg cells through an autonomous TH2 pathway, which impairs Treg cell function, resulting in excessive conventional TH2 cell responses. In summary, our study suggests a previously unappreciated role of CIS in the regulation of Treg cell stability through a feedback control of the Treg-intrinsic TH2 program and in the inhibition of allergic airway inflammation. These findings provide novel insights into the stabilization of Treg cells and may suggest therapeutic intervention in human allergic airway diseases.

MATERIALS AND METHODS

Animals

Cis^{fl/fl};Foxp3-YfpCre (*Cis*^{fl/fl,Cre}) mice on the C57BL/6 (B6);129 F1 background were generated by breeding B6.*Cis*^{fl/fl,Cre} with 129.*Cis*^{fl/+} mice; *Cis*^{fl/+};Cre (or *Cis*^{fl/fl} or *Cis*^{fl/+};Cre) littermates were used as control. B6.*Cis*^{fl/fl,Cre} mice were obtained by breeding B6.*Cis*^{fl/fl} mice with B6.Foxp3-YfpCre mice (purchased from the Jackson Laboratory),⁴⁰ whereas 129.*Cis*^{fl/+} mice were obtained by crossing B6.*Cis*^{fl/fl} with 129 mice for seven to eight generations. *Cis*^{-/-};GFP

mice on the B6;129 F1 background were generated by breeding B6.*Cis*^{+/-};GFP mice (obtained by crossing B6.*Cis*^{-/-} mice with B6.Foxp3-Gfp, ref. 18,41) with 129.*Cis*^{+/-} mice; *Cis*^{+/-};GFP littermates were used as control. Similarly, *Cis*^{fl/fl,Cre} R26Y and *Cis*^{fl/+};Cre R26Y fate-mapping mice on the B6;129 F1 background were generated as described above. R26Y (*Rosa26*^{stop}-eYfp) mice were purchased from the Jackson Laboratory.⁴² All mice were housed in the specific pathogen-free animal facility at the University of New Mexico Health Sciences Center. All experiments were performed with protocols approved by the Institutional Animal Care and Use Committee of the University of New Mexico.

Induction of experimental allergic asthma

For induction of allergic asthma, 6–8-week-old sex-matched mice were immunized intranasally with 25 μ g papain and 50 μ g chicken OVA for three times on days 0, 1, and 14. In some experiments, Treg cells (0.5 \times 10⁶ cells per recipient) isolated from indicated mice by using a Treg isolation kit (Miltenyi Biotec) were co-transferred intraperitoneally with Treg-depleted *Cis*-sufficient CD4⁺ T cells (5 \times 10⁶ cells per recipient) into *Rag1*^{-/-} mice, and the recipient mice were subjected to induction of asthma. On day 15, BALFs were collected for analysis of airway infiltrates as described.^{29,30} Additionally, BALFs, LLNs and spleens were collected for analysis of cellular profiles. LLN and spleen cells (4 \times 10⁶ cells ml⁻¹) were recalled with various concentrations of ova for 3 days and the supernatants were collected for measurement of cytokines expression by ELISA using a standard protocol.

In vitro Treg cell differentiation

CD4⁺CD25⁻CD44^{lo}C62L⁺-naive T cells were isolated from indicated mice, and activated by plate-bound α -CD3/ α -CD28 in a Treg-polarizing condition (100 U ml⁻¹ IL-2, 2 ng ml⁻¹ TGF β , 2 μ g ml⁻¹ anti-IFN- γ with or without 5 μ g ml⁻¹ anti-IL-4 as indicated).

In vitro Treg suppression assay

Wild-type (WT) naive CD4⁺ T cells were co-cultured with purified Treg cells at indicated ratios of Treg to naive CD4⁺ T cells in the presence of irradiated splenic antigen-presenting cells and anti-CD3 for 3 days. In some experiments, anti-IL-4 (11B11)-neutralizing antibodies (10 μ g ml⁻¹) were added as indicated. Proliferation was assessed by ³H-thymidine incorporation for the final 8 h before harvest.

Real-time quantitative PCR

Gene mRNA expression levels were determined by RT-qPCR using primers in Supplementary Table 1. Data were normalized to an *Actb* reference gene.

Chromatin immunoprecipitation

Cell lysates were prepared as described.²⁸ The lysates were first pre-cleared with protein G magnetic beads at 4 °C for 30 m. After removal of the protein G beads, supernatants were collected and incubated with an antibody against the target protein or a control antibody overnight at 4 °C, followed by protein G magnetic beads incubation for 2 h at 4 °C on day 2 morning. The bead–antibody–chromatin complexes were magnetically separated and washed two times with low salt TE buffer and additionally two times with high salt TE buffer. Finally, the bead–antibody–chromatin complexes were collected and re-suspended in TE buffer for reverse crosslink in the presence of 0.2 M NaCl for 4 h at 65 °C. The samples were then subjected for qPCR. The primers used were in Supplementary Table 2. The antibodies used were in Supplementary Table 3.

Flow cytometry

For intracellular cytokine stain, the cells were collected and stimulated with phorbol 12-myristate 13-acetate and ionomycin in the presence of Golgi-stop for 4 h. Phosphor-protein stain of pSTAT6



was performed using a previously described protocol with minor modifications.⁴³ In brief, the cells were collected in vivo or in vitro and fixed by 1.6% paraformaldehyde for 20 min, re-suspended in 50% ethanol for 1 min, and permeabilized with methanol for 20 min. The resulting cells were stained with anti-pSTAT6 in cold 0.1% bovine serum albumin-phosphate-buffered saline for 30 min. The flow cytometry antibodies were in Supplementary Table 3.

Statistical analysis

The statistical significance of differences between groups was calculated with the unpaired Student's *t* test. *P* values of 0.05 or less were considered significant.

ACKNOWLEDGEMENTS

This work was supported in part by NIH Grants AI116772 and AI142200 (X.O.Y.), GM121176 (X.O.Y., M.L.; PD, V. Deretic), and DK110439 (M.L.). We acknowledge the University of New Mexico Flow Cytometry Facility supported by NIH CA118100 and the Central South University collaboration program supported by NSFC 81828004. H. Z. was a recipient of Careers in Immunology Fellowship, American Association of Immunologists and Ruby Fellowship.

AUTHOR CONTRIBUTIONS

X.O.Y., C.D., and M.L. designed the project. H.Z., X.W., D.W., X.O.Y., R.-L.J., E.F.C., C.J.C., and Q.Z. performed the experiments. H.Z., X.W., D.W., and X.O.Y. analyzed the data and prepared the manuscript.

ADDITIONAL INFORMATION

The online version of this article (<https://doi.org/10.1038/s41385-019-0236-3>) contains supplementary material, which is available to authorized users.

Competing interests: The authors declare no competing interests.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES

1. Rudensky, A. Y. Regulatory T cells and Foxp3. *Immunol. Rev.* **241**, 260–268 (2011).
2. Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. *Cell* **133**, 775–787 (2008).
3. Li, X., Liang, Y., LeBlanc, M., Benner, C. & Zheng, Y. Function of a Foxp3 cis-element in protecting regulatory T cell identity. *Cell* **158**, 734–748 (2014).
4. Fontenot, J. D. & Rudensky, A. Y. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. *Nat. Immunol.* **6**, 331–337 (2005).
5. Williams, L. M. & Rudensky, A. Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. *Nat. Immunol.* **8**, 277–284 (2007).
6. Bennett, C. L. & Ochs, H. D. IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. *Curr. Opin. Pediatr.* **13**, 533–538 (2001).
7. Fontenot, J. D., Gavin, M. A. & Rudensky, A. Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. *Nat. Immunol.* **4**, 330–336 (2003).
8. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. *Science* **299**, 1057–1061 (2003).
9. McMurchy, A. N., Bushell, A., Levings, M. K. & Wood, K. J. Moving to tolerance: clinical application of T regulatory cells. *Semin Immunol.* **23**, 304–313 (2011).
10. Game, D. S., Cao, X. & Jiang, S. Regulatory T cells: the cunning fox and its clinical application. *Sci. Signal* **1**, mr3 (2008).
11. Brusko, T. & Bluestone, J. Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation. *Eur. J. Immunol.* **38**, 931–934 (2008).
12. Marek-Trzonkowska, N., Mysliwiec, M., Siebert, J. & Trzonkowski, P. Clinical application of regulatory T cells in type 1 diabetes. *Pediatr. Diabetes* **14**, 322–332 (2013).
13. Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector T(H)17 and regulatory T cells. *Nature* **441**, 235–238 (2006).

14. Dardalhon, V. et al. IL-4 inhibits TGF-beta-induced Foxp3(+) T cells and, together with TGF-beta, generates IL-9(+) IL-10(+) Foxp3(-) effector T cells. *Nat. Immunol.* **9**, 1347–1355 (2008).
15. Kastner, L., Dwyer, D. & Qin, F. X. F. Synergistic effect of IL-6 and IL-4 in driving fate revision of natural Foxp3(+) regulatory T cells. *J. Immunol.* **185**, 5778–5786 (2010).
16. Xu, L. L., Kitani, A., Fuss, I. & Strober, W. Cutting edge: regulatory T cells induce CD4(+)CD25(-)Foxp3(-) T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. *J. Immunol.* **178**, 6725–6729 (2007).
17. Jin, H. S., Park, Y., Elly, C. & Liu, Y. C. Itch expression by Treg cells controls Th2 inflammatory responses. *J. Clin. Invest.* **123**, 4923–4934 (2013).
18. Yang, X. O. et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. *Immunity* **29**, 44–56 (2008).
19. Takaki, H. et al. STAT6 inhibits TGF-beta1-mediated Foxp3 induction through direct binding to the Foxp3 promoter, which is reverted by retinoic acid receptor. *J. Biol. Chem.* **283**, 14955–14962 (2008).
20. Chapoval, S., Dasgupta, P., Dorsey, N. J. & Keegan, A. D. Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL-4 and STAT6. *J. Leukoc. Biol.* **87**, 1011–1018 (2010).
21. Xu, L. et al. Positive and negative transcriptional regulation of the Foxp3 gene is mediated by access and binding of the Smad3 protein to enhancer I. *Immunity* **33**, 313–325 (2010).
22. O'Shea, J. J., Gadina, M. & Schreiber, R. D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. *Cell* **109**(Suppl.), S121–S131 (2002).
23. Palmer, D. C. & Restifo, N. P. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. *Trends Immunol.* **30**, 592–602 (2009).
24. Yoshimura, A., Naka, T. & Kubo, M. SOCS proteins, cytokine signalling and immune regulation. *Nat. Rev. Immunol.* **7**, 454–465 (2007).
25. Yoshimura, A. et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. *EMBO J.* **14**, 2816–2826 (1995).
26. Aman, M. J. et al. CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signaling. *J. Biol. Chem.* **274**, 30266–30272 (1999).
27. Matsumoto, A. et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. *Blood* **89**, 3148–3154 (1997).
28. Yang, X. O. et al. The signaling suppressor CIS controls proallergic T cell development and allergic airway inflammation. *Nat. Immunol.* **14**, 732–740 (2013).
29. Zheng, H. et al. Leptin enhances TH2 and ILC2 responses in allergic airway disease. *J. Biol. Chem.* **291**, 22043–22052 (2016).
30. Zheng, H. et al. Leptin promotes allergic airway inflammation through targeting the unfolded protein response pathway. *Sci. Rep.* **1**, 8905 (2018).
31. Yao, Z. et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3. *Blood* **109**, 4368–4375 (2007).
32. Feng, Y. et al. Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus. *Cell* **158**, 749–763 (2014).
33. Zheng, Y. et al. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. *Nature* **463**, 808–812 (2010).
34. Josefowicz, S. Z., Lu, L. F. & Rudensky, A. Y. Regulatory T cells: mechanisms of differentiation and function. *Annu. Rev. Immunol.* **30**, 531–564 (2012).
35. Takahashi, R. et al. SOCS1 is essential for regulatory T cell functions by preventing loss of Foxp3 expression as well as IFN-gamma and IL-17A production. *J. Exp. Med.* **208**, 2055–2067 (2011).
36. Knosp, C. A. et al. Regulation of Foxp3+ inducible regulatory T cell stability by SOCS2. *J. Immunol.* **190**, 3235–3245 (2013).
37. Yagi, R., Zhu, J. & Paul, W. E. An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation. *Int. Immunol.* **23**, 415–420 (2011).
38. Wang, Y., Su, M. A. & Wan, Y. Y. An essential role of the transcription factor GATA-3 for the function of regulatory T cells. *Immunity* **35**, 337–348 (2011).
39. Wohlfert, E. A. et al. GATA3 controls Foxp3(+) regulatory T cell fate during inflammation in mice. *J. Clin. Invest.* **121**, 4503–4515 (2011).
40. Rubtsov, Y. P. et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. *Immunity* **28**, 546–558 (2008).
41. Fontenot, J. D. et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. *Immunity* **22**, 329–341 (2005).
42. Srinivas, S. et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. *BMC Dev. Biol.* **1**, 4 (2001).
43. Krutzik, P. O. & Nolan, G. P. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. *Cytom. A* **55**, 61–70 (2003).